JP2022546703A - 耳鳴りの治療のためのオキシトシン組成物 - Google Patents

耳鳴りの治療のためのオキシトシン組成物 Download PDF

Info

Publication number
JP2022546703A
JP2022546703A JP2022513237A JP2022513237A JP2022546703A JP 2022546703 A JP2022546703 A JP 2022546703A JP 2022513237 A JP2022513237 A JP 2022513237A JP 2022513237 A JP2022513237 A JP 2022513237A JP 2022546703 A JP2022546703 A JP 2022546703A
Authority
JP
Japan
Prior art keywords
oxytocin
composition
tinnitus
individual
thickening agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2022513237A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546703A5 (enExample
Inventor
ニューマン，ローレンス，シー
クレイマー，ジェイムス
Original Assignee
ニューヨーク ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューヨーク ユニバーシティ filed Critical ニューヨーク ユニバーシティ
Publication of JP2022546703A publication Critical patent/JP2022546703A/ja
Publication of JP2022546703A5 publication Critical patent/JP2022546703A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2022513237A 2019-08-29 2020-08-31 耳鳴りの治療のためのオキシトシン組成物 Ceased JP2022546703A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962893363P 2019-08-29 2019-08-29
US62/893,363 2019-08-29
PCT/US2020/048736 WO2021042029A1 (en) 2019-08-29 2020-08-31 Oxytocin compositions for treatment of tinnitus

Publications (2)

Publication Number Publication Date
JP2022546703A true JP2022546703A (ja) 2022-11-07
JP2022546703A5 JP2022546703A5 (enExample) 2023-09-11

Family

ID=74680528

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022513237A Ceased JP2022546703A (ja) 2019-08-29 2020-08-31 耳鳴りの治療のためのオキシトシン組成物

Country Status (7)

Country Link
US (1) US11241477B2 (enExample)
EP (1) EP4021410A4 (enExample)
JP (1) JP2022546703A (enExample)
AU (1) AU2020335930B2 (enExample)
BR (1) BR112022003687A2 (enExample)
CA (1) CA3152988A1 (enExample)
WO (1) WO2021042029A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4299059A1 (en) 2022-07-01 2024-01-03 Labelic Analysis, S.L. Composition for the treatment of tinnitus
US20250255930A1 (en) * 2024-02-08 2025-08-14 Maskbegone Llc Methods of treatment of tinnitus using derivatives of oxytocin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009506071A (ja) * 2005-08-26 2009-02-12 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
US20100311655A1 (en) * 2007-06-07 2010-12-09 Mdrna, Inc. Intranasal carbetocin formulations and methods for the treatment of autism
US20130085106A1 (en) * 2010-05-19 2013-04-04 The University Of North Carolina At Chapel Hill Methods and formulations for oxytocin treatment of substance use, psychiatric and other disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140608A1 (en) 2010-05-14 2011-11-17 Keating Charlotte L Neuropsychopharmacological treatment regimes for treating psychological disorders
EP2680913B1 (en) 2011-03-03 2020-05-06 Impel NeuroPharma Inc. Nasal drug delivery device
CN107376071B (zh) 2011-05-09 2021-07-09 英倍尔药业股份有限公司 用于将化合物递送到使用者的上部嗅觉区的喷嘴
US20140066373A1 (en) 2012-08-29 2014-03-06 Albert Einstein College Of Medicine Of Yeshiva University Treating diabetes with oxytocin or oxytocin analogs
US11744838B2 (en) * 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
ES2949052T3 (es) * 2014-11-19 2023-09-25 Optinose Inc Administración intranasal
PL3242676T3 (pl) 2015-01-07 2024-07-15 Tonix Pharma Limited Preparaty oksytocyny zawierające magnez i sposoby ich stosowania

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009506071A (ja) * 2005-08-26 2009-02-12 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
US20100311655A1 (en) * 2007-06-07 2010-12-09 Mdrna, Inc. Intranasal carbetocin formulations and methods for the treatment of autism
US20130085106A1 (en) * 2010-05-19 2013-04-04 The University Of North Carolina At Chapel Hill Methods and formulations for oxytocin treatment of substance use, psychiatric and other disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRONT. NEUROL., vol. 8, JPN6024029806, 2017, pages 494 - 1, ISSN: 0005536688 *

Also Published As

Publication number Publication date
WO2021042029A1 (en) 2021-03-04
AU2020335930A1 (en) 2022-03-24
US11241477B2 (en) 2022-02-08
EP4021410A1 (en) 2022-07-06
CA3152988A1 (en) 2021-03-04
BR112022003687A2 (pt) 2022-05-24
EP4021410A4 (en) 2023-12-06
AU2020335930B2 (en) 2025-06-05
US20210060119A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
JP7756953B2 (ja) マグネシウム含有オキシトシン製剤および使用の方法
JP2003512325A (ja) 感冒およびインフルエンザ様症状の予防並びに治療用組成物、並びにそれらの使用方法
JP2012522783A5 (enExample)
US20200281970A1 (en) Method of treating gingivitis using low concentration hypochlorous acid solutions
ES2985515T3 (es) Nuevo régimen de dosificación para polipéptido intestinal vasoactivo inhalado
US11241477B2 (en) Oxytocin compositions for treatment of tinnitus
RU2019111715A (ru) Окисляющие аммиак микроорганизмы для применения и доставки в интраназальной системе
US20170312335A1 (en) Topical use of prg4 for treatment of allergy and symptoms of inflammation
US20250255930A1 (en) Methods of treatment of tinnitus using derivatives of oxytocin
US20260053883A1 (en) Oxytocin compositions for treatment of visual snow syndrome
SG11201809581RA (en) Method and product for caries treatment
EA202191506A1 (ru) Терапевтическая композиция интраназального лидокаина
WO2023059716A8 (en) Compositions and methods for levodopa delivery
WO2023144614A1 (en) Nasal compositions and methods thereof
JPH10130148A (ja) ネブライザー用組成物
US20140377356A1 (en) Inhalation Composition for Treating Respiratory Tract Infections
EP4285920A1 (en) Composition for use as an antiviral in the form of nasal drops and in nebulisers
HK40108141A (en) Magnesium-containing oxytocin formulations and methods of use
CA3020179C (en) Magnesium-containing oxytocin formulations and methods of use
JP2002338461A (ja) 鼻疾患治療薬
US20140377355A1 (en) Levofloxacin Inhalation Composition
JPWO2006006674A1 (ja) Ｐｔｈを含有する経粘膜投与剤
Class et al. Patent application title: Method for the treatment and prevention of Alzheimer's disease and central nervous system dysfunction Inventors: Steven Lehrer (New York, NY, US)
US20140179597A1 (en) Method for the treatment and prevention of Alzheimer's disease and central nervous system dysfunction

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230901

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240731

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250519

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250829

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20251126